Cantor Fitzgerald Reiterates “Overweight” Rating for Perspective Therapeutics (NYSE:CATX)

Cantor Fitzgerald reiterated their overweight rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report report published on Tuesday, Benzinga reports.

Several other analysts have also recently weighed in on CATX. Royal Bank of Canada reiterated an outperform rating and issued a $30.00 price target on shares of Perspective Therapeutics in a report on Friday, June 14th. Oppenheimer restated an outperform rating on shares of Perspective Therapeutics in a report on Tuesday, June 18th. B. Riley boosted their target price on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the company a buy rating in a report on Tuesday, April 9th. Finally, Lifesci Capital reaffirmed an outperform rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of Buy and a consensus price target of $19.00.

Perspective Therapeutics Trading Up 1.0 %

Shares of CATX opened at $9.97 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98. Perspective Therapeutics has a 1-year low of $2.05 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. The firm had revenue of $0.33 million for the quarter. On average, sell-side analysts expect that Perspective Therapeutics will post -1.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Perspective Therapeutics news, Director Lori A. Woods purchased 4,587 shares of Perspective Therapeutics stock in a transaction dated Friday, June 14th. The stock was purchased at an average price of $10.90 per share, with a total value of $49,998.30. Following the transaction, the director now directly owns 159,985 shares of the company’s stock, valued at $1,743,836.50. The purchase was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Robert F. Williamson III acquired 3,003 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was bought at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the purchase, the director now owns 36,879 shares in the company, valued at approximately $490,490.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lori A. Woods acquired 4,587 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average price of $10.90 per share, with a total value of $49,998.30. Following the completion of the purchase, the director now owns 159,985 shares in the company, valued at approximately $1,743,836.50. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 30,814 shares of company stock valued at $385,487. 3.52% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $138,000. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $15,511,000. Affinity Asset Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $6,069,000. Vanguard Group Inc. raised its holdings in shares of Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in Perspective Therapeutics during the 1st quarter valued at $40,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.